Jun 2026 (Q2 FY26) — Aug 13, 2026
Abeona Therapeutics Q2 FY26 — ZEVASKYN Commercial Rollout Progresses with QTC Expansion and NTAP Status
Read the full callAbeona Therapeutics (ABEO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Abeona Therapeutics earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 11.4 | +2745.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -120.0 | +5578.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -20.2 | −118.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$4.41 −0.45% · −$0.02
Performance −18.0% 1Y
1Y: $5.38 on 17 Oct 2025 → $4.41. High $7.46 (12 Aug 2026), low $4.17 (11 Nov 2025).
- Previous close
- $4.43
- 52-week range
- $4.17 – $7.46
- One year
- −19.82%
Overview
- Symbol
- ABEO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Abeona Therapeutics earnings calls (ABEO)
Financials
What the filings say
Net profit, year on year: −119% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | — | 0 | — | 5 | 9 | 11 |
| Expenses | 15 | 17 | 20 | 23 | 24 | 28 | 32 | 25 |
| Operating profit | -15 | -17 | -20 | -23 | -24 | -23 | -23 | -14 |
| Operating margin | — | — | — | −5698.0% | — | −422.7% | −264.1% | −120.0% |
| Other income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | -0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -30 | -9 | -12 | 124 | -20 | -21 | -17 | -20 |
| Tax rate | — | — | — | 12.5% | 74.7% | 1.0% | −0.0% | — |
| Net profit | -30 | -9 | -12 | 109 | -5 | -20 | -17 | -20 |
| EPS ($ per share) | -0.63 | — | -0.24 | 2.07 | -0.10 | — | -0.30 | -0.35 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Reserves | -410 | -486 | -571 | -656 | -695 | -750 | -813 | -742 |
| Total liabilities | 40 | 45 | 49 | 37 | 37 | 49 | 65 | 60 |
| Fixed assets | 9 | 13 | 11 | 12 | 6 | 4 | 4 | 10 |
| Investments | 66 | — | 82 | 12 | 38 | 38 | 74 | 113 |
| Total assets | 174 | 223 | 151 | 80 | 64 | 64 | 109 | 220 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39 | -63 | -35 | -66 | -43 | -37 | -56 | -76 |
| Cash from investing | -85 | 60 | -84 | 66 | -24 | 0 | -39 | 105 |
| Cash from financing | 5 | 114 | 2 | 25 | 43 | 37 | 104 | 26 |
| Net cash flow | -119 | 111 | -117 | 25 | -24 | 0 | 9 | 55 |
| Capital expenditure | -9 | -6 | -1 | -4 | -0 | -0 | -2 | -8 |
| Free cash flow | -48 | -69 | -36 | -70 | -44 | -37 | -58 | -84 |
Insider filings
53 filings between Nov 13, 2025 and Sep 29, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$3.57M
38 sales by 9 insiders
16% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
Also filed: 1 gift, 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Seshadri Vishwas | — | $1.51M | Sep 29, 2026 |
| Vazzano Joseph Walter | — | $598.8K | Sep 29, 2026 |
| Alvino Mark | — | $275.4K | Sep 1, 2026 |
| Vasanthavada Madhav | — | $264.3K | Sep 29, 2026 |
| O'Malley Brendan M. | — | $250.6K | Sep 29, 2026 |
| Crombez Eric | — | $227.5K | May 15, 2026 |
| Silverstein Christine Berni | — | $205.9K | Jun 15, 2026 |
| Alland Leila | — | $157.0K | Jun 30, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 6,727 | $34.7K |
| Sep 29, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 9,191 | $47.4K |
| Sep 29, 2026 | Seshadri Vishwas Chief Executive Officer | Sale | 19,608 | $101.1K |
| Sep 29, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 4,902 | $25.3K |
| Sep 1, 2026 | Alvino Mark Director | Sale | 15,000 | $88.0K |
| Jul 21, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 1,478 | $9.7K |
| Jul 9, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 24,880 | $173.3K |
| Jul 9, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 12,606 | $87.8K |
| Jul 9, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 12,050 | $83.9K |
| Jul 9, 2026 | Seshadri Vishwas Chief Executive Officer | Sale | 67,971 | $473.3K |
| Jun 30, 2026 | Alland Leila Director | Sale | 11,000 | $65.1K |
| Jun 16, 2026 | Vasanthavada Madhav Chief Commercial Officer | Other | 222 | $1.3K |
| Jun 15, 2026 | Silverstein Christine Berni Director | Sale | 18,160 | $103.7K |
| Jun 9, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale 10b5-1 plan | 13,421 | $71.2K |
| Jun 9, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale 10b5-1 plan | 25,646 | $138.3K |
| Jun 9, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 6,305 | $33.4K |
| Jun 9, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 5,450 | $28.9K |
| Jun 9, 2026 | Seshadri Vishwas Chief Executive Officer | Sale | 31,916 | $169.3K |
| Jun 8, 2026 | Seshadri Vishwas Chief Executive Officer | Sale | 24,428 | $132.6K |
| Jun 8, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 4,170 | $22.6K |
| Jun 8, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale 10b5-1 plan | 10,271 | $55.8K |
| Jun 8, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 4,826 | $26.2K |
| May 26, 2026 | Alvino Mark Director | Gift | 500 | $0 |
| May 22, 2026 | Alvino Mark Director | Sale | 6,500 | $35.5K |
| May 15, 2026 | Crombez Eric Director | Sale 10b5-1 plan | 26,143 | $144.6K |
| May 11, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 5,548 | $33.1K |
| Apr 1, 2026 | Goldan Keith A. Director | Award | 32,751 | $0 |
| Mar 31, 2026 | Seshadri Vishwas Chief Executive Officer | Sale 10b5-1 plan | 29,985 | $131.5K |
| Mar 16, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 785 | $3.7K |
| Feb 2, 2026 | Silverstein Christine Berni Director | Sale | 20,070 | $102.2K |
| Feb 2, 2026 | Alvino Mark Director | Sale | 2,000 | $10.2K |
| Feb 2, 2026 | Wuchterl Donald A. Director | Sale | 14,814 | $75.4K |
| Feb 2, 2026 | Alland Leila Director | Sale | 18,065 | $92.0K |
| Feb 2, 2026 | Crombez Eric Director | Sale | 16,284 | $82.9K |
| Jan 26, 2026 | Crombez Eric Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Zeiher Bernhardt G Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Wuchterl Donald A. Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Silverstein Christine Berni Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Amoroso Michael Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Charles Faith L. Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Alvino Mark Director | Award | 37,313 | $0 |
| Jan 26, 2026 | Alland Leila Director | Award | 37,313 | $0 |
| Jan 22, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 12,610 | $66.7K |
| Jan 22, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 18,666 | $99.5K |
| Jan 22, 2026 | Seshadri Vishwas Chief Executive Officer | Sale | 69,832 | $372.3K |
| Jan 22, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 13,578 | $72.4K |
| Jan 21, 2026 | Alvino Mark Director | Sale | 13,500 | $70.6K |
| Jan 20, 2026 | Vasanthavada Madhav Chief Commercial Officer | Award | 76,621 | $0 |
| Jan 20, 2026 | Vazzano Joseph Walter Chief Financial Officer | Award | 133,595 | $0 |
| Jan 20, 2026 | Seshadri Vishwas Chief Executive Officer | Award | 365,422 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ABEONA THERAPEUTICS INC.
Free account. Everything above stays public.
Write why you follow ABEONA THERAPEUTICS INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading